AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's Disease
Key Highlights
- ➤ABBV-466 achieved 30.2% Week 12 endoscopic remission, versus 21.3% and 18.0% monotherapy
- ➤Week 24 remission reached 40.5% with ABBV-466, versus 22.4% and 20.0% monotherapy
- ➤TARGET-CD enrolled 300 moderate-to-severe Crohn’s disease patients across three treatment groups
- ➤ABBV-466 showed intestinal repair and barrier restoration by Week 12
- ➤Serious adverse events were 10.4% with ABBV-466, comparable to monotherapy arms
Expert Statements
Kori Wallace, M.D., Vice President, Global Head of Immunology Clinical Development, AbbVie
“ABBV-466 reflects how we are building the next generation of our inflammatory bowel disease (IBD) portfolio, leveraging insights from our own research to address disease pathways that may remain active even when a central inflammatory pathway is inhibited.”
Kori Wallace, M.D., Vice President, Global Head of Immunology Clinical Development, AbbVie
“Our research pointed to evidence of α4β7-driven inflammation despite risankizumab's IL-23 p19 inhibition, leading us to augment risankizumab with a novel α4β7 inhibitor, trosunilimab.”
Kori Wallace, M.D., Vice President, Global Head of Immunology Clinical Development, AbbVie
“The TARGET-CD results reinforce our strategy of advancing therapies designed around the complex biology of Crohn's disease.”
Remo Panaccione, M.D., Professor of Medicine and Director of the Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, University of Calgary
“Many patients with Crohn's disease move from one advanced therapy to the next and still have active inflammation in the bowel, even when their symptoms improve.”
Remo Panaccione, M.D., Professor of Medicine and Director of the Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, University of Calgary
“Endoscopic remission is a goal we aim for, because ongoing inflammation can drive disease progression over time.”
Remo Panaccione, M.D., Professor of Medicine and Director of the Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, University of Calgary
“What stands out in the TARGET-CD Phase 2a study is that a dual-targeting approach reached that goal more often than either therapy alone in a heavily pretreated population.”
AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's Disease PR Newswire
* In a Phase 2a study, ABBV-466 achieved higher endoscopic remission rates in patients with Crohn's disease than either anti-IL-23 p19 or anti-α4β7 monotherapy at Week 12, the primary endpoint. The treatment difference between ABBV-466 and the monotherapy groups further increased at Week 24(1) * Gene expression analysis showed that ABBV-466 treated Crohn's disease patients experienced intestinal tissue repair and barrier restoration by Week 12, with tissue remodeling and metabolic changes reported at Week 24(1) * The results will be presented as a late-breaker at the 2026 Annual United European Gastroenterology Week Congress NORTH CHICAGO, Ill., Oct. 19, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its investigational ABBV-466, a novel dual-targeting therapy against IL-23 p19 and integrin α4β7, demonstrated higher rates of endoscopic remission(a) at Week 12 than either monotherapy in patients with Crohn's disease (CD). The difference in endoscopic remission(a) rates between ABBV-466 and monotherapy groups further increased at Week 24. The findings are from the TARGET-CD study, an ongoing open-label, treat-through, Phase 2a platform study in patients with moderate to severe CD.(1,2) The findings will be presented as a late-breaking abstract at the ongoing 2026 Annual United European Gastroenterology Week (UEGW) Congress in Barcelona, October 17–20.
Get started
Create a free account to read the full story.